This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT05616013 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 507 participants |
| Design | Interventional, Randomized, Factorial, Masking: Double |
| Conditions | Obesity; Obese; Overweight or Obesity |
| Interventions | Bimagrumab; Semaglutide; Placebo |
| Start | Nov 16, 2022 |
| Primary completion | May 16, 2024 |
| Study completion | Jun 14, 2025 |
| Results posted | Yes, in the registry |
| Registry last updated | Jul 8, 2026 |
| Collaborators | Versanis Bio, Inc. |
Compounds on this site that cite this trial
What the registry says the trial is about
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change From Baseline in Body Weight at Week 48 | Baseline, Week 48 |
41 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
